Shares of LeMaitre Vascular Inc (NASDAQ:LMAT) have been assigned an average recommendation of “Hold” from the seven analysts that are currently covering the company, MarketBeat Ratings reports. Five research analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $30.33.

LMAT has been the subject of a number of recent research reports. ValuEngine downgraded shares of W&T Offshore from a “hold” rating to a “sell” rating in a research note on Friday, April 26th. BidaskClub cut shares of Westport Fuel Systems from a “buy” rating to a “hold” rating in a report on Friday. Zacks Investment Research cut shares of GENEL ENERGY PL/ADR from a “buy” rating to a “hold” rating in a report on Tuesday, May 7th. Finally, Barrington Research set a $64.00 target price on shares of SurModics and gave the company a “buy” rating in a report on Thursday, May 2nd.

Shares of LeMaitre Vascular stock traded down $0.48 during trading hours on Friday, reaching $30.42. 91,439 shares of the company’s stock were exchanged, compared to its average volume of 96,733. The business’s 50 day moving average is $27.50. LeMaitre Vascular has a fifty-two week low of $21.79 and a fifty-two week high of $38.99. The firm has a market cap of $598.39 million, a PE ratio of 36.21, a P/E/G ratio of 3.05 and a beta of 1.14.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings data on Wednesday, May 1st. The medical instruments supplier reported $0.17 EPS for the quarter, missing the Zacks’ consensus estimate of $0.19 by ($0.02). LeMaitre Vascular had a return on equity of 16.76% and a net margin of 20.92%. The business had revenue of $28.48 million for the quarter, compared to analyst estimates of $27.94 million. During the same quarter in the prior year, the company earned $0.19 earnings per share. The company’s quarterly revenue was up 9.6% on a year-over-year basis. Research analysts predict that LeMaitre Vascular will post 0.83 EPS for the current year.

Hedge funds have recently modified their holdings of the company. BlackRock Inc. raised its holdings in shares of LeMaitre Vascular by 2.2% in the 4th quarter. BlackRock Inc. now owns 2,601,309 shares of the medical instruments supplier’s stock valued at $61,496,000 after purchasing an additional 56,161 shares during the period. Bank of New York Mellon Corp raised its holdings in shares of LeMaitre Vascular by 1.5% in the 4th quarter. Bank of New York Mellon Corp now owns 256,990 shares of the medical instruments supplier’s stock valued at $6,075,000 after purchasing an additional 3,841 shares during the period. Ranger Investment Management L.P. raised its holdings in shares of LeMaitre Vascular by 1.3% in the 4th quarter. Ranger Investment Management L.P. now owns 732,380 shares of the medical instruments supplier’s stock valued at $17,313,000 after purchasing an additional 9,688 shares during the period. Oregon Public Employees Retirement Fund bought a new stake in shares of LeMaitre Vascular in the 4th quarter valued at about $143,000. Finally, Geode Capital Management LLC raised its holdings in LeMaitre Vascular by 11.0% in the 4th quarter. Geode Capital Management LLC now owns 200,496 shares of the medical instruments supplier’s stock valued at $4,739,000 after acquiring an additional 19,828 shares during the period. 77.16% of the stock is currently owned by institutional investors.

About LeMaitre Vascular

LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature.

Recommended Story: Why is the Consumer Price Index (CPI) important?

Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.